Mifamurtide in osteosarcoma - A practical review

Drugs of Today

Volumn 46, Issue 5, 2010, Pages 327-337

  Anderson, Peter M ^a   Tomaras, M ^a   McConnell, K ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; DRUG CARRIER; FOLINIC ACID; IBUPROFEN; IFOSFAMIDE; MEPACT; MESNA; METHOTREXATE; MIFAMURTIDE; MURAMYL TRIPEPTIDE; PARACETAMOL; PEGINTERFERON; PETHIDINE; RAZOXANE; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CHILL; DRUG DESIGN; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG INDUSTRY; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; EVENT FREE SURVIVAL; FEVER; HUMAN; IMMUNITY; IMMUNOCOMPETENT CELL; IN VIVO STUDY; LUNG METASTASIS; MACROPHAGE ACTIVATION; NORTH AMERICA; OSTEOSARCOMA; OUTER MEMBRANE; OVERALL SURVIVAL; PATIENT CARE; PREMEDICATION; RECOMMENDED DRUG DOSE; REVIEW; RIGOR; TARGET CELL; TREATMENT OUTCOME;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; IMMUNOLOGIC FACTORS; LIPOSOMES; OSTEOSARCOMA; PHOSPHATIDYLETHANOLAMINES; SURVIVAL;

EID: 77954752953     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.5.1500076     Document Type: Review

References (72)

1. Blankenberg, F.G., Katsikis, P.D., Tait, J.F. et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA 1998, 95(11): 6349-54.
2. Kornbluth, R.S. The immunological potential of apoptotic debris produced by tumor cells and during HIV infection. Immunol Lett 1994, 43(1-2): 125-32.
3. Shiratsuchi, A., Nakanishi, Y. Phosphatidylserine-mediated phagocytosis of anticancer drug-treated cells by macrophages. J Biochem 1999, 126(6): 1101-6. (Pubitemid 30014457)
4. Johnson, H., Scorrano, L., Korsmeyer, S.J., Ley, T.J. Cell death induced by granzyme C. Blood 2003, 101(8): 3093-101.
5. Kleinerman, E.S., Maeda, M., Jaffe, N. Liposome-encapsulated muramyl tripeptide: A new biologic response modifier for the treatment of osteosarcoma. Cancer Treat Res 1993, 62: 101-7.
6. Kleinerman, E.S., Raymond, A.K., Bucana, C.D. et al. Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol lmmunother 1992, 34(4): 211-20.
7. Kleinerman, E.S. Biologic therapy for osteosarcoma using liposome-encapsuloted muramyl tripeptide. Hematol Oncol Clin North Am 1995, 9(4): 927-38.
8. Murray, J.L., Kleinerman, E.S., Cunningham, J.E. et al. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J Clin Oncol 1989, 7(12): 1915-25.
9. Gano, J.B., Kleinerman, E.S. Liposomal MTP-PE. J Pediatr Oncol Nurs 1994, 11(4): 161-3.
10. Kleinerman, E.S., Snyder, J.S., Jaffe, N. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethonolamine in children with osteosarcoma. J Clin Oncol 1991, 9(2): 259-67.
11. Hudson, M.M., Snyder, J.S., Jaffe, N., Kleinerman, E.S. In vitro and in vivo effect of adriamycin therapy on monocyte activation by liposome- encapsulated immunomodulators. Cancer Res 1988, 48(18): 5256-63.
12. Kleinerman, E.S., Jaffe, N. Liposomal MTP-PE for the adjuvant therapy of osteosarcoma. Prog Clin Biol Res 1990, 343: 263-79.
13. Kleinerman, E.S., Erickson, K.L., Schroit, A.J., Fogler, W.E., Fidler, I.J. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res 1983, 43(5): 2010-4.
14. Maeda, M., Knowles, R.D., Kleinerman, E.S. Muramyl tripeptide phosphatidylethonolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro. Cancer Commun 1991, 3(10-11): 313-21.
15. Asano, T., Fujimaki, W., McWatters, A., An, T., Matsushima, K., Kleinerman, E.S. Effect of Adriamycin on liposomal muramyl tripeptide's ability to up-regulate monocyte cytokine expression. Cancer Immunol Immunother 1993, 37(6): 408-11.
16. Asano, T., Kleinerman, E.S. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. J Immunother Emphasis Tumor Immunol 1993, 14(4): 286-92.
17. Fujimaki, W., Griffin, J.R., Kleinerman, E.S. Effect of Ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethonolamine (CGP 19835A): Can ibuprofen reduce fever and chills without compromising immune stimulation? Cancer Immunol Immunother 1993, 36(1): 45-51.
18. Kleinerman, E.S., Gano, J.B., Johnston, D.A., Benjamin, R.S., Jaffe, N. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol 1995, 18(2): 93-9.
19. Kleinerman, E.S., Meyers, P.A., Raymond, A.K., Gano, J.B., Jia, S.F., Jaffe, N., Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation. J Immunother Emphasis Tumor Immunol 1995, 17(3): 181-93.
20. Risin, D., Kleinerman, E.S., Umezu, Y., Pizzini, R.P., Balch, C.M., Pellis, N.R. Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated muramyltripeptide-phosphatidylethanolamine. Cancer Immunol lmmunother 1995, 40(1): 57-64.
21. Fogler, W.E., Wade, R., Brundish, D.E., Fidler, I.J. Distribution and fate of free and liposome-encapsulated (3H)nor-muramyl dipeptide and (3H)muramyl tripeptide phosphatidylethonolamine in mice. J Immunol 1985, 135(2): 1372-7.
22. Meyers, P.A. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther 2009, 9(8): 1035-49.
23. Mori, K., Ando, K., Heymann, D. Liposomal muramyl tripeptide phosphatidyl ethanolamine: A safe and effective agent against osteosarcoma pulmonary metastases. Expert Rev Anticancer Ther 2008, 8(2): 151-9.
24. Anderson, P. Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma. Future Oncol 2006, 2(3): 333-43.
25. Kleinerman, E.S., Jia, S.F., Griffin, J., Seibel, N.L., Benjamin, R.S., Jaffe, N., Phase II study of liposomal muramyl tripeptide in osteosarcoma: The cytokine cascade and monocyte activation following administration. J Clin Oncol 1992, 10(8): 1310-6.
26. Meyers, P.A., Schwartz, C.L., Krailo, M. et al. Osteosarcoma: A randomized, prospective trial of the addition ofifosfomide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005, 23(9): 2004-11.
27. Meyers, P.A., Schwartz, C.L., Krailo, M.D. et al. Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. J Clin Oncol 2008, 26(4): 633-8.
28. Chou, A.J., Kleinerman, E.S., Krailo, M.D. et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: A report from the Children's Oncology Croup. Cancer 2009, 115(22): 5339-48.
29. Hawkins, D.S. and Arndt, C.A. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 2003, 98(11): 2447-56.
30. Maki, R.G. Gemcitabine and docetaxel in metastatic sarcoma: Past, present, and future. Oncologist 2007, 12(8): 999-1006.
31. Maki, R.G., Wathen, J.K., Patel, S.R. et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: Results of sarcoma alliance for research through collaboration study 002 (corrected). J Clin Oncol 2007, 25(19): 2755-63.
32. Okuno, S., Ryan, L.M., Edmonson, J.H., Priebat, D.A., Blum, R.H. Phase II trial of gemcitabine in advanced sarcomas. Cancer 2002, 94(12): 3225-9.
33. Navid, F., Willert, J.R., McCarville, M.B., Furman, W., Watkins, A., Roberts, W., Daw, N.C. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 2008, 113(2): 419-25.
34. Anderson, P., Kornguth, D., Ahrar, K. et al. Recurrent, refractory, metastatic, and/or unresectable pediatric sarcomas: Treatment options for young people that are off the roadmap. Pediatric Health 2008, 2: 605-15.
35. Goorin, A.M., Harris, M.B., Bernstein, M. et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol 2002, 20(2): 426-33.
36. Harris, M.B., Gieser, R., Goorin, A.M. et al. Treatment of metastatic osteosarcoma at diagnosis: A Pediatric Oncology Group Study. J Clin Oncol 1998, 16(11): 3641-8.
37. Merimsky, O., Meller, I., Kollender, Y., Issakov, J., Flusser, G., Inbar, M. Gemcitabine in bone sarcoma resistant to Doxorubicin-based chemotherapy. Sarcoma 2000, 4(1-2): 7-10. (Pubitemid 30480275)
38. Koshkina, N.V., Khanna, C., Mendoza, A., Guan, H., DeLauter, L., Kleinerman, E.S. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: The role of the Fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res 2007, 5(10): 991-9.
39. Lafleur, E.A., Koshkina, N.V., Stewart, J., Jia, S.F., Worth, L.L., Duan, X., Kleinerman, E.S. Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clin Cancer Res 2004, 10(23): 8114-9.
40. Gordon, N., Arndt, C.A., Hawkins, D.S. et al. Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol 2005, 27(11): 611-5.
41. Gordon, N., Koshkina, N.V., Jia, S.F., Khanna, C., Mendoza, A, Worth, L.L., Kleinerman, E.S. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res 2007, 13(15 Pt 1): 4503-10.
42. Bielack, S.S., Kempf-Bielack, B., Branscheid, D. Second and subsequent recurrences of osteosarcoma: Presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol 2009, 27(4): 557-65.
43. Kim, H.J., Chalmers, P.N., Morris, C.D. Pediatric osteogenic sarcoma. Curr Opin Pediatr 2009.
44. Whelan, J., Seddon, B., Perisoglou, M. Management of osteosarcoma. Curr Treat Options Oncol 2006, 7(6): 444-55.
45. Muller, C.R., Smeland, S., Bauer, H.C., Saeter, G., Strander, H. Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: Long term results of the Karolinska Hospital series. Acta Oncol 2005, 44(5): 475-80.
46. Strander, H., Bauer, H.C., Brosjö, O. et al. Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study. Acta Oncol 1995, 34(6): 877-80.
47. Whelan, J., Patterson, D., Perisoglou, M., Bielack, S., Marina, N., Smeland, S., Bernstein, M. The role of interferons in the treatment of osteosarcoma. Pediatr Blood Cancer 2010, 54(3): 350-4.
48. Strander, H. Interferons and osteosarcoma. Cytokine Growth Factor Rev 2007, 18(5-6): 373-80.
49. Manara, M.C., Serra, M., Benini, S., Picci, P., Scotlandi, K. Effectiveness of Type I interferons in the treatment of multidrug resistant osteosarcoma cells. Int J Oncol 2004, 24(2): 365-72.
50. Chou, A.J., Geller, D.S., Gorlick, R. Therapy for osteosarcoma: Where do we go from here? Paediatr Drugs 2008, 10(5): 315-27.
51. Moore, C., Eslin, D., Levy, A., Roberton, J., Guisti, V., Sutphin, R. Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma. Pediatr Blood Cancer, 2010. 54: in press.
52. De Angulo, G., Hernandez, M., Morales-Arias, J., Herzog, C.E., Anderson, P., Wolff, J., Kleinerman, E.S. Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma. J Pediatr Hematol Oncol 2007, 29(1): 48-52. (Pubitemid 46143025)
53. Cooper, L.J., Ausubel, L., Gutierrez, M. et al. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma. Cytotherapy 2006, 8(2): 105-17.
54. Huland, E., Heinzer, H., Jörres, R.A., Loppow, D., Huland, H. Therapeutic approaches in metastatic renal cell carcinoma: local immunotherapy. Urologe A 2004, (43, Suppl. 3): 140-4.
55. Fehniger, T.A., Cooper, M.A., Caligiuri, M.A. Interleukin-2 and interleukin-15: Immunotherapy for cancer. Cytokine Growth Factor Rev 2002, 13(2): 169-83.
56. Vaisman, D.N., McCarthy, A.D., Cortizo, A.M. Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: Role of divalent cations. Biol Trace Elem Res 2005, 104(2): 131-40.
57. Bacci, G., Longhi, A., Ferrari, S. et al. Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: Recent experience at Rizzoli Institute. Oncol Rep 2002, 9(1): 171-5.
58. Horie, N., Murata, H., Kimura, S. et al. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma. Br J Cancer 2007, 96(2): 255-61.
59. Benassi, M.S., Chiechi, A., Ponticelli, F. et al. Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. Cancer Lett 2007, 250(2): 194-205.
60. Ory, B., Blanchard, F., Battaglia. S., Gouin, F., Rédini, F, Heymann, D. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol 2007, 71(1): 333-43.
61. Kubista, B., Trieb, K., Sevelda, F. et al. Anticancer effects of zoledronic acid against human osteosarcoma cells. J Orthop Res 2006, 24(6): 1145-52.
62. Ory, B., Heymann, M.F., Kamijo, A., Gouin, F., Heymann, D., Redini, F. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 2005, 104(11): 2522-9.
63. Evdokiou, A., Labrinidis, A., Bouralexis, S., Hay, S., Findlay, D.M. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone 2003, 33(2): 216-28.
64. Anderson, P., Kopp, L., Anderson, N., Cornelius, K., Herzog, C., Hughes, D., Huh, W. Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma). Expert Opin Investig Drugs 2008, 17(11): 1703-15.
65. Anderson, P.M., Wiseman, G.A., Erlandson, L., Rodriguez, V., Trotz, B., Dubansky, S.A., Albritton, K. Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin Cancer Res 2005, 11(19 Pt 1): 6895-900.
66. Anderson, P.M., Wiseman, G.A., Dispenzieri, A. et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol, 2002. 20(1): 189-96.
67. Bruland, O.S. Skretting, A., Solheim, P.O., Aas, M. Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach. Acta Oncol, 1996. 35(3): 381-4.
68. Bruland, O.S., Nilsson, S., Fisher, D.R., Larsen, R.H. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: Adjuvant or alternative to conventional modalities? Clin Cancer Res, 2006. 12(20 Pt 2): 6250s-6257s.
69. Nilsson, S., Franzéu, L., Parker, C. et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer. A randomised, multicentre, placebo-controlled phase II study. Lancet Oncol, 2007. 8(7): 587-94.
70. Nilsson, S., Larsen, R.H., Fossa, S.D. et al. First clinical experience with alpha-emitting rodium-223 in the treatment of skeletal metastases. Clin Cancer Res, 2005. 11(12): 4451-9.
71. Kerr, C. (223)Ra targets skeletal metastases and spares normal tissue. Lancet Oncol 2002, 3(8): 453.
72. Messerschmitt, P.J., Garcia, P.J., Abdul-Karim, F.W., Greenfield, E.M., Getty, P.J. Osteosarcoma. J Am Acad Orthop Surg 2009, 17(8): 515-27.